Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
L-Vincristine is a preclinical-stage liposomal nanocarrier formulation of vincristine being developed by InnoMedica Holding AG for the treatment of leukemia. The drug utilizes InnoMedica's proprietary liposomal nanocarrier technology platform to deliver the active ingredient vincristine, a vinca alkaloid chemotherapy agent. Vincristine works by disrupting microtubule formation during cell division, specifically by binding to tubulin and inhibiting its polymerization, making it effective against rapidly dividing cancer cells. The liposomal formulation is designed to improve drug delivery and potentially reduce the dose-limiting neurotoxicity associated with conventional vincristine while maintaining or enhancing therapeutic efficacy.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on L-Vincristine.